Singapore
AUM Biosciences, founded in 2018, is a biotechnology company headquartered in Singapore. The company focuses on developing precision oncology therapeutics with a unique multi-faceted inhibition approach to effectively combat and reverse cancer resistance. This innovative strategy sets them apart in the competitive oncology sector.
Under the slogan, "Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance," AUM Biosciences is positioning itself as a pioneer in a growing market that is increasingly demanding more effective cancer treatments.
The company's latest financial milestone was a substantial $27.00M Series A investment, received on October 12, 2021. This round was backed by notable investors like Everlife, SPRIM, and The Agency for Science, Technology and Research. The robust support from these investors signals a strong vote of confidence in the company's strategic vision and growth potential.
